If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient to patient, a discovery that adds to a growing base of knowledge important for developing more effective precision therapies.
Findings from the study, led by Han Liang, Ph.D., associate professor of Bioinformatics and Computational Biology, and Gordon Mills, M.D., Ph.D., chair of Systems Biology, were published in the April 26 online issue of Cancer Cell.
Liang’s and Mills’ team discovered how a particular type of RNA editing called adenosine to inosine (A-to-I) RNA plays a key role in protein variation in cancer cells. RNA editing is the process by which genetic information is altered in the RNA molecule. Once thought rare in humans and other vertebrates, RNA editing is now recognized as widespread in the human genome.
Since cancer can arise from vastly different protein types and mutations, the promise of individualizing therapies for each patient is reliant upon a better understanding of the protein “genome,” an area of study called proteomics. Understanding the molecular mechanism contributing to protein variation and diversity is a key question in cancer research today, with significant clinical applications for cancer treatment.
“Using data from The Cancer Genome Atlas and the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium, our study provides large-scale direct evidence that A-to-I RNA editing is a source of proteomic diversity in cancer cells,” said Liang. “RNA editing represents a new paradigm for understanding the molecular basis of cancer and developing strategies for precision cancer medicine. If a protein is only highly edited in tumor proteins, but not in normal proteins, then it’s possible that a specific drug could be designed to inhibit the edited mutant protein.”
It has long been known that A-to-I RNA editing allows cells to tweak the RNA molecule resulting in nucleotide sequences which alter DNA “instructions” for how proteins are generated and how they are assembled within the cell.
The researchers demonstrated how A-to-I RNA editing contributes to protein diversity in breast cancer by making changes in amino acid sequences. They found one protein, known as coatomer subunit alpha (COPA), increased cancer cell proliferation, migration and invasion in vitro, following A-to-I RNA editing.
“Collectively, our study suggests that A-to-I RNA editing contributes to protein diversity at least in some cancers,” said Mills. “It is an area of study that deserves more effort from the cancer research community to elucidate the molecular basis of cancers, and potentially developing prognostic and therapeutic approaches.”
The Latest on: Precision cancer medicine
via Google News
The Latest on: Precision cancer medicine
- Cancer genomic tests often aren’t done to guideline; germline data presents unique issueson January 23, 2020 at 4:28 pm
Just as it does with treatments, the National Comprehensive Cancer Network (NCCN ... These were the conclusions of a standing-room only panel on the topic at the Precision Medicine World Conference.
- Precision medicine startup Notable starts trial to test AI platform in blood cancer patientson January 23, 2020 at 1:23 pm
The study enrolled 21 patients with myelodysplastic syndrome – a type of blood cancer that can progress to acute myeloid leukemia – whose disease was refractory to drugs known as hypomethylating ...
- For People with a Rare Mouth Cancer, a Targeted Drug Can Be Lifesavingon January 23, 2020 at 1:15 pm
The lump was on one of his salivary glands. Most tumors that form in these glands are benign (noncancerous). But pathology tests revealed that Dr. Kuchler had salivary gland cancer. This study is a ...
- Refining breast cancer classification by multiplexed imagingon January 23, 2020 at 9:47 am
This heterogeneity makes it challenging to ascertain the severity of a tumor and assess its molecular subtype, thereby affecting the precision of diagnosis and the choice of the most effective ...
- The year in new drugs: Looking back and aheadon January 22, 2020 at 10:04 pm
Precision medicine has moved the needle to make things more patient ... If this is successful, it could transform the field of personalized cancer care. Finally, Biogen has a novel antibody drug for ...
- Personalis, Inc. to Present at Precision Medicine World Conference 2020on January 22, 2020 at 8:15 am
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Precision Medicine World ...
- Genialis and Oncologie Collaborate on Precision Medicine Initiative in Gastric Canceron January 22, 2020 at 5:54 am
Genialis, a leader in applied data science for the development of precision medicines, today announced a collaborative partnership ... Early work between the two companies has thus far focused on ...
- Editing RNA delivers precision strike on triple-negative breast canceron January 21, 2020 at 9:43 am
The move toward targeted anti-cancer treatments has produced better outcomes with fewer side-effects for many breast cancer patients. But so far, advances in precision medicine haven't reached people ...
- miR Scientific® Introduces New Paradigm for Precision Medicine at PMWC 2020on January 21, 2020 at 6:13 am
/PRNewswire/ -- miR Scientific LLC, a precision bioscience company focused on comprehensive disease detection and management, announced that CEO and ...
via Bing News